Qualigen therapeutics partners with td2 for phase 1 clinical development of qn-302 for the treatment of advanced or metastatic solid tumors

Carlsbad, calif., aug. 17, 2023 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, announced today it is partnering with translational drug development (td2) as the contract research organization (cro) to conduct the phase 1 clinical development of lead drug candidate qn-302. qualigen received us fda ind clearance earlier this month to initiate a phase 1 clinical trial of qn-302, a small molecule g-quadruplex (g4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.
QLGN Ratings Summary
QLGN Quant Ranking